10-O-[1-propyl-3-N-carbamoylcholesteryl]-triethyleneglycol-1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite
Potential therapeutic oligonucleotides must permeate the cell membrane for optimal activity. The addition of lipophilic groups to an oligonucleotide would be expected to enhance cellular uptake/membrane permeation. The use of Cholesterol-labelled oligos and the consequent improvement in activity has been described. We have designed our Cholesteryl products with triethyleneglycol (TEG) spacers for maximum solubility.
| Specifications | |
|---|---|
| Diluent | Anhydrous Acetonitrile |
| Storage | Freezer storage, -10 to -30°C, dry |
| Stability | 2-3 days |
The table below show pack size data and, for solutions, dilution and approximate coupling based on normal priming procedures.
| Catalog # | Pack Size | Grams/Pack | 0.1M Dil. (mL) | Approximate Number of Additions | |||||
|---|---|---|---|---|---|---|---|---|---|
| LV40 | LV200 | 40nm | 0.2μm | 1μm | 10μm | ||||
| 10-1976-02 | 0.25 g | .25grams | 3.05 | 88.33 | 53 | 33.13 | 24.09 | 17.67 | 4.42 |
| 10-1976-90 | 100 µmol | .082grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| 10-1976-95 | 50 µmol | .041grams | 0.5 | 3.33 | 2 | 1.25 | 0.91 | 0.67 | 0.17 |
| Catalog # | Pack Size | Grams/Pack | Dilution (mL) | Approximate Number of Additions | ||||
|---|---|---|---|---|---|---|---|---|
| Molarity | 50nm | 0.2μm | 1μm | 15μm | ||||
| 10-1976-02 | 0.25 g | .25grams | 4.55 | 0.07 | 84.6 | 52.88 | 38.45 | 5.29 |
| 10-1976-90 | 100 µmol | .082grams | 1.5 | 0.07 | 23.6 | 14.75 | 10.73 | 1.48 |
| 10-1976-95 | 50 µmol | .041grams | 0.75 | 0.07 | 8.6 | 5.38 | 3.91 | 0.54 |
